COMPANY PROFILE

Jiangsu Vcare

Explore full profile

Provides RandD of innovative drugs, transfer of generic drug technology, the production and sales of pharmaceuticals

Nanjing City, ChinaFounded 2010Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2026

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Jiangsu Vcare

V Care Pharmatech operates in the pharmaceutical industry, focusing on the sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company serves clients involved in research and development (R&D) and those operating in regions without intellectual property (IP) conflicts. V Care Pharmatech's business model revolves around providing high-quality chemical compounds essential for drug development and production. The company generates revenue through the direct sale of these intermediates and APIs, catering to pharmaceutical companies, research institutions, and other entities in the healthcare sector. By ensuring compliance with regional IP regulations, V Care Pharmatech mitigates legal risks for its clients, enabling smoother and more efficient R&D processes.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Nanjing City, China
Open positions: None listed
Dealroom signal: 24.0/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Jiangsu Vcare.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Jun 2026	$28M	$110M	Huadian Investment · Hongyao Science and Technology · Hongcheng Investment · Huarui Capital	↗
SERIES COther financing	Jan 2025	$28M	$715M	SDIC Fund Management · Yangtze River Fund	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Jiangsu Vcare website traffic

Latest recorded traffic for Jiangsu Vcare is 410 monthly website visits, down 48.8% over the last three months.

Latest monthly visits410 3-month web change-48.8%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ABAiolos BioRevolutionizing the treatment landscape for respiratory disease and other immune conditions	San Francisco, United States	Acquired	3	$245M	$1B
ZDZoo Pharma DynamicsInnovative animal healthcare solutions through advanced research and development	San Antonio, United States	Operational
ALAlderley Lighthouse LabsClinically led laboratory pathology and diagnostic testing services	Macclesfield, United Kingdom	Operational
NKNK:IODeveloping technologies to improve cancer treatment	London, United Kingdom	Operational
OCOne CuregenDeveloping diverse technologies necessary for the development of first-in-class global anticancer drugs	Daejeon, South Korea	Operational
LTLirum TherapeuticsClinical-stage targeted therapies for oncology and autoimmune diseases	New York City, United States	Operational
AIAlexander Shulgin Research InstituteWe are a psychedelics discovery, development, and educational organization dedicated to continuing and extending the work of Dr. Alexander “Sasha” Shulgin	Lafayette, United States	Operational
BIBioSynchronicityBioSynchronicity has developed the innovative and accurate C-SyncTM COVID-19 Antigen Test	Spokane, United States	Operational